Shares of Envista Holdings Corp. rose 2.3% in premarket trading on Thursday after JPMorgan upgraded the dental equipment maker to Overweight from Neutral.
Analyst Lilia-Celine B Lozada raised the price target to $32 from $29, citing expectations of improved execution and a more durable organic growth algorithm ahead of Envista’s September 17 Investor Day. The upgrade reflects confidence that the company’s valuation has not kept pace with strengthening fundamentals.
Lozada noted that consistency and quality in the MedTech sector have become increasingly scarce, and Envista’s potential to sustain mid-single-digit underlying growth could justify a higher earnings multiple than its current valuation suggests. Street estimates project core growth of roughly 3.5% in 2027 and beyond, an increase from the prior core growth framework range of 2-4%.
Management has indicated that the medium-term core growth framework may modestly exceed the prior range, with potential expansion to 2.5-4.5% or 3-4%. The upgrade follows a period of operational improvement and sets the stage for further investor scrutiny at the upcoming event.
